title: EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway.
abstract: The scaffold protein ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50, also known as NHERF1 or NHERF) inhibits epidermal growth factor (EGF)-induced breast cancer cell proliferation after 3 days by blocking EGF receptor (EGFR) phosphorylation. The loss of EBP50 stimulates EGFR activity and induces the appearance of epithelial-to-mesenchymal transition phenotypic features in biliary cancer cells. However, the involvement of EBP50 in breast cancer migration and invasion remains unknown. We report that EBP50 inhibits the migration and invasion of breast cancer cells by inhibiting the phosphorylation of LIN-11, Isl1, and MEC-3 protein domain kinase, as well as cofilin. This phosphorylation is a critical step in cofilin recycling and actin polymerization mediating cytoskeletal rearrangement. Additionally, EGF-induced phosphorylation of Akt and mTOR was suppressed by upregulation of EBP50. Our results indicate that EBP50 is significantly involved in breast cancer invasion/metastasis via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway.
authors.affiliation: Medicine Research Center, Weifang Medical University, Weifang, 261053, People's Republic of China.
authors.forename: Hongli
authors.initials: H
authors.lastname: Li
authors.forename: Baogang
authors.initials: B
authors.lastname: Zhang
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Liu
authors.forename: Chonggao
authors.initials: C
authors.lastname: Yin
mesh_terms: D051339:Actin Depolymerizing Factors / Q000378:metabolism; D000199:Actins / Q000378:metabolism; D000818:Animals; D001940:Breast / Q000737:chemistry / Q000378:metabolism; D001943:Breast Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology*; D004815:Epidermal Growth Factor / Q000378:metabolism; D005260:Female; D006801:Humans; D054461:Lim Kinases / Q000378:metabolism; D016513:Mice, SCID; D009361:Neoplasm Invasiveness / Q000503:physiopathology; D009374:Neoplasms, Experimental / Q000737:chemistry / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D017923:Sodium-Hydrogen Exchangers / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism
chemical_list: D051339:Actin Depolymerizing Factors; D000199:Actins; D004815:Epidermal Growth Factor; D054461:Lim Kinases; D019869:Phosphatidylinositol 3-Kinases; D010750:Phosphoproteins; D051057:Proto-Oncogene Proteins c-akt; D017923:Sodium-Hydrogen Exchangers; D058570:TOR Serine-Threonine Kinases; C093376:sodium-hydrogen exchanger regulatory factor; C546842:MTOR protein, human; C515892:LIMK1 protein, human